• Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGY
  • At Week 52, 85.3% of patients receiving IQIRVO achieved normalization of ALP compared with 23.3% receiving placebo and was generally well tolerated
  • Findings add to growing evidence supporting ALP normalization as an achievable treatment goal in PBC 

PARIS, FRANCE, 5 NOVEMBER 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data from the ELSPIRE Phase III study in people living with primary biliary cholangitis (PBC) and alkaline phosphatase (ALP) levels between 1- 1.67× upper limit of normal (ULN). At Week 52, 85.3% of patients receiving IQIRVO achieved normalization of ALP, a biochemical measure of disease activity, compared with 23.3% receiving placebo (p<0.0001). The findings will be presented as late-breaking data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026 and simultaneously published in HEPATOLOGY. In addition, these data with an expanded patient population, are being shared with regulatory authorities.

Globenewswire